Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595819 | 0.81 | LOXL2 (0.47) | ALDH1A1HRH4AHR | |
| SCHEMBL15717620 | 0.81 | LOXL2 (0.47) | ALDH1A1HRH4AHR | |
| SCHEMBL31663239 | 0.81 | LOXL2 (0.36) | CA12CA1CA9 | |
| SCHEMBL31663343 | 0.80 | NR3C1 (0.42) | ITK | |
| SCHEMBL14745993 | 0.77 | IDO1 (0.39) | NOS1METAP2IDO1CSNK2A1DUT | |
| SCHEMBL21062158 | 0.77 | DUT (0.30) | DUT | |
| SCHEMBL29997290 | 0.77 | DUT (0.30) | DUT | |
| SCHEMBL14745758 | 0.76 | LPL (0.35) | CA1CA9 | |
| SCHEMBL6429168 | 0.75 | LMNA (0.40) | NOS1METAP2DYRK1ALMNARAB9A | |
| SCHEMBL7677098 | 0.75 | LOXL2 (0.51) | LMNARAB9AALDH1A1HRH4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| EP-2750504-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | NOS1 1949/4885METAP2 1493/4885DYRK1A 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.